Abstract:e20607 Background: Although the targeted therapy and immunotherapy have become the first line options for selected stage IV non-small cell lung cancer (NSCLC) patients. However, there are instances where certain patients are not administered targeted therapy or immunotherapy due to a variety of factors, chemotherapy and radiotherapy remain the main way to treat such patients. This study aimed to construct a prognostic nomogram for patients with stage IV NSCLC treated with chemotherapy combined with high-dose (≥ 60 Gy) thoracic radiotherapy. Methods: The nomogram was based on a retrospective study of 335 patients with stage IV NSCLC who treated with chemotherapy combined with high-dose (≥ 60 Gy) thoracic radiotherapy were hospitalized between January 2010 and January 2018(patient did not receive TKI therapy or immunotherapy). The patients were randomly assigned to either a primary cohort (n = 234) or a validation cohort (n = 101) at a ratio of 7 : 3. In the primary cohort, a univariate analysis of the clinical or therapeutic factors that may predict OS was performed using a Cox regression model, with P < 0.05 indicating statistical significance. The variables from the univariate analysis that affected OS significantly were included in the Cox regression model for the multivariate analysis. A nomogram was then created based on the results of multivariate analysis and using the “rms,” “foreign,” and “survival” R version 4.0.3 software packages. The discriminatory ability of the nomogram was measured using the area under the curve (AUC) of a receiver operating curve (ROC). Results: Multivariate logistic regression analysis revealed that malignant pericardial effusion, adrenal metastasis, elevated lactate dehydrogenase levels, and excessive planning target volume were independent risk factors for poorer 1–3 year overall survival (OS), while a higher radiotherapy dose for the primary lesion was associated with better OS. Nomogram prediction models were constructed using these five variables. The AUC of the ROC for 1-year, 2-year, and 3-year OS in the primary cohort were 0.685, 0.729, and 0.816, respectively. In the validation cohort, the AUC of the ROC for 1-year, 2-year, and 3-year OS were 0.706, 0.749, and 0.797, respectively. The Kaplan-Meier survival analysis showed that differentiation between the high-risk group and low-risk group using the prediction model had a direct, significant effect on survival in both the primary cohort ( P < 0.001) and validation cohort ( P = 0.004). Conclusions: The nomogram model constructed in this study may be used to objectively predict the prognosis and OS of patients with stage IV NSCLC treated with chemotherapy and high-dose thoracic radiotherapy. Identify patients who may not benefit from high-dose thoracic radiotherapy prior to treatment to avoid overtreatment.

Nomogram to Predict the Overall Survival for Patients Underwent Preoperative Radiation Therapy with Chemotherapy

A Reliable Nomogram is Identified to Predict the Overall Survival for Patients with Esophageal Squamous Cancer after Chemoradiation Therapy Followed by Surgery

Clinical Nomogram for Predicting Survival of Esophageal Cancer Patients after Esophagectomy

Analysis of prognostic factors and nomogram for predicting survival for patients with locally resectable esophageal cancer after preoperative chemoradiation therapy

A neotype nomogram based on accessible clinical indicators to predict the overall survival of esophageal cancer patients underwent radical resection

Prognostic Nomogram for Predicting Long-Term Overall Survival of Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Plus Surgery: A Population-Based Study

A Prognostic Nomogram for Overall Survival after Neoadjuvant Radiotherapy or Chemoradiotherapy in Thoracic Esophageal Squamous Cell Carcinoma: a Retrospective Analysis

A nomogram from the SEER database for predicting the prognosis of patients with non-small cell lung cancer

OA 03.07 Developing Prognostic Nomogram and Evaluating Its Role in Personalized Adjuvant Chemotherapy for Patients with ESCC

Nomogram constructed by immunological and inflammatory indicators for predicting prognosis of patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy plus surgery

The nomogram for the prediction of overall survival after surgery in patients in early-stage NSCLC based on SEER database and external validation cohort

Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery

Prognostic Nomogram for Previously Untreated Patients with Esophageal Squamous Cell Carcinoma after Esophagectomy Followed by Adjuvant Chemotherapy

Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma

Nomogram to predict overall survival for patients with non-metastatic cervical esophageal cancer: a SEER-based population study

Prognostic Nomogram for Overall Survival in Patients with Stage IV Non-Small Cell Lung Cancer Treated with Chemotherapy Combined with High-Dose Thoracic Radiotherapy.

The Evaluation of a SEER-Based Nomogram in Predicting the Survival of Patients Treated with Neoadjuvant Therapy Followed by Esophagectomy

Development of a prognostic nomogram for esophageal squamous cell carcinoma patients received radiotherapy based on clinical risk factors

A national multicenter retrospective clinical study to develop a prognostic nomogram for patients with esophageal squamous cell carcinoma based on definitive radiotherapy (3JECROG R-03A)

The Development of a Nomogram and the Prognostic Prediction Value of Patients with Esophageal Squamous Cell Carcinoma Undergoing Radical Radiotherapy.